<DOC>
	<DOCNO>NCT02885181</DOCNO>
	<brief_summary>The primary objective study evaluate effect GS-9876 versus placebo treatment sign symptom rheumatoid arthritis ( RA ) participant active RA despite methotrexate ( MTX ) therapy inadequate response MTX ( either alone combination biological disease modify anti-rheumatic drug [ bDMARDs ] ) .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy GS-9876 Participants With Active Rheumatoid Arthritis Background Therapy With Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Active RA disease define : tender joint count ( TJC ) ≥ 6 ( 68 ) , swollen joint count ( SJC ) ≥ 6 ( 66 ) screen Day 1 Inadequate response treatment oral parenteral MTX 7.5 25 mg/week continuously least 12 week , least 6 week stable dose ( defined change prescription ) prior first dose study drug Participants must receive folic folinic acid supplementation stable dose . Prior treatment Bcell deplete agent ( eg , rituximab ) , unless 6 month prior first dose study drug document return CD19+ cell screen Prior treatment commercially available investigational spleen tyrosine kinase ( SYK ) inhibitor Concurrent treatment conventional synthetic DMARD ( csDMARD ) MTX and/or hydroxychloroquine ( HCQ ) ( prior csDMARD treatment allow appropriate wash define protocol ) Concurrent treatment biological disease modify antirheumatic drug ( bDMARD ) ( prior bDMARD treatment allow appropriate wash define protocol ) . Prior failure treatment bDMARDs exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>